Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 2:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 4,235 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Experimental 1 Clear all
Terminated Phase 1 Interventional

A Study of Safety of PBCLN-003 Following Antibiotic Therapy in Subjects With C.Difficile-associated Diarrhea

NCT03793686
View directory record Official record
Conditions
Clostridium Difficile Diarrhea
Interventions
PBCLN-003, Placebo
Drug
Lead sponsor
Prolacta Bioscience
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Idaho Falls, Idaho
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 11, 2026, 2:33 AM EDT
Withdrawn Phase 2 Interventional

Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM

NCT06352866
View directory record Official record
Conditions
Multiple Myeloma, Cytokine Release Syndrome, Refractory Multiple Myeloma, Immune Effector Cell Associated Neurotoxicity Syndrome
Interventions
Siltuximab, Teclistamab(FDA-approved)
Drug
Lead sponsor
Jack Khouri, MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Oct 11, 2026, 2:33 AM EDT
Terminated Phase 3 Interventional

Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7

NCT04777851
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Regorafenib in combination with pembrolizumab, Loco-regional therapy
Drug · Procedure
Lead sponsor
Translational Research in Oncology
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 11, 2026, 2:33 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Repeated CBD Administration and Cannabis Outcomes

NCT07434895
View directory record Official record
Conditions
Cannabis, Abuse Liability, Experimental Pain in Healthy Human Participants
Interventions
Cannabidiol, Medium Dose, Cannabidiol, Higher Dose, Active Inhaled Cannabis, Placebo Cannabidiol, Placebo Inhaled Cannabis
Drug
Lead sponsor
Hannah Harris
Other
Eligibility
18 Years to 55 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 11, 2026, 2:33 AM EDT
Not listed Not applicable Interventional

FallsTalk Falls Prevention Program for Caregivers and Persons With Memory Loss or Dementia

NCT03961386
View directory record Official record
Conditions
Falls (Accidents) in Old Age
Interventions
FallsTalk-C, FallsTalk
Behavioral
Lead sponsor
Brookside Research & Development Company
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Freeland, Washington
Source: ClinicalTrials.gov public record
Updated Jun 6, 2019 · Synced Oct 11, 2026, 2:33 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Using a Personalized Decision Support Tool to Help People With Type 1 Diabetes Manage Exercise

NCT07226583
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Exercise Physiology
Interventions
Standard-of-Care Guidance (SoC), Usual Care (UC), netIOB & Exercise Toolkit (NEXT), Continuous Glucose Monitoring, Continuous Ketone Monitoring
Behavioral · Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 11, 2026, 2:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Mechanisms of Altered Ventilatory Control in Heart Failure

NCT02421341
View directory record Official record
Conditions
Heart Failure
Interventions
Fentanyl, Catheters, Exercise, DEXA, Pulmonary Function Tests, Blood Draw, Chemosensitivity Test, Placebo
Drug · Procedure · Other + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Oct 11, 2026, 2:33 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Imaging Sex Differences in Smoking-Induced Pulmonary Inflammation

NCT03721822
View directory record Official record
Conditions
Smoking, Cigarette, Smoking E-cigarette, Healthy Volunteer
Interventions
[18F]NOS
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 45 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 11, 2026, 2:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

LycoRed 40051 Product as a Countermeasure to Exercise Stress

NCT02369666
View directory record Official record
Conditions
Inflammation
Interventions
LycoRed (code 40051) product, Placebo
Dietary Supplement
Lead sponsor
Appalachian State University
Other
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Kannapolis, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 16, 2015 · Synced Oct 11, 2026, 2:33 AM EDT
Recruiting Early Phase 1 Interventional

Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence

NCT02446431
View directory record Official record
Conditions
Solid Tumor
Interventions
Bevacizumab, Cyclophosphamide, Valproic Acid, Temsirolimus
Drug
Lead sponsor
Miller Children's & Women's Hospital Long Beach
Other
Eligibility
12 Months to 31 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2029
U.S. locations
2
States / cities
Long Beach, California • Orange, California
Source: ClinicalTrials.gov public record
Updated May 18, 2015 · Synced Oct 11, 2026, 2:33 AM EDT
Terminated Phase 2 Interventional Results available

Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases

NCT05746481
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Tiragolumab, Atezolizumab, Pemetrexed, Carboplatin
Drug
Lead sponsor
Liza Villaruz, MD
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 11, 2026, 2:33 AM EDT
Not listed Phase 1Phase 2 Interventional

Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies

NCT04092673
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
eFT226, Sotorasib, Fulvestrant, Abemaciclib, Trastuzumab
Drug
Lead sponsor
Effector Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
14
States / cities
Los Angeles, California • Newport Beach, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 21, 2024 · Synced Oct 11, 2026, 2:33 AM EDT
Not listed Not applicable Interventional

Clinical and Electrographic Changes in Responsive Neurostimulation System (RNS) Patients with Acupuncture Treatment

NCT04677751
View directory record Official record
Conditions
Epilepsy
Interventions
Acupuncture intervention
Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
15 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 11, 2026, 2:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Newborn Health Information Study

NCT00820677
View directory record Official record
Conditions
Infant, Newborn
Interventions
DVD/Video
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 14, 2009 · Synced Oct 11, 2026, 2:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Fire Fighter Fatigue Management Program: Operation Fight Fatigue

NCT01672502
View directory record Official record
Conditions
Shift-Work Sleep Disorder, Insomnia, Restless Leg Syndrome, Obstructive Sleep Apnea, Impaired Driving
Interventions
Sleep health education provided via a web-based program, Sleep disorder detection and treatment, Optimization of Sleep in Fire Station
Behavioral · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
620 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Oct 11, 2026, 2:33 AM EDT
Recruiting Phase 1 Interventional

Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors

NCT07261631
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer, Colorectal Cancer, Soft Tissue Sarcoma
Interventions
68Ga-NNS309, 177Lu-DFC413
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 11, 2026, 2:33 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Does Omeprazole Decrease Intestinal Calcium Absorption?

NCT00582972
View directory record Official record
Conditions
Osteoporosis, Achlorhydria, GERD, Hip Fracture
Interventions
Omeprazole
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 15, 2013 · Synced Oct 11, 2026, 2:33 AM EDT
Completed Phase 1 Interventional

CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies

NCT04450069
View directory record Official record
Conditions
Relapsed/Refractory B-cell Lymphomas, Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Chronic Lymphocytic Leukemia (CLL), Marginal Zone Lymphoma (MZL), Mantle Cell Lymphoma, Small Lymphocytic Lymphoma (SLL), Primary Mediastinal Large B Cell Lymphoma, Transformed Follicular Lymphoma, Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma, Burkitt Lymphoma
Interventions
CLBR001 and SWI019
Combination Product
Lead sponsor
Calibr, a division of Scripps Research
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
8
States / cities
Duarte, California • San Diego, California • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Oct 11, 2026, 2:33 AM EDT
Terminated Phase 1 Interventional

An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies

NCT01929941
View directory record Official record
Conditions
Solid Tumor, Hodgkin's Lymphoma, NHL (Non-Hodgkin Lymphoma), Pancreatic Cancer, Breast Cancer, UC (Ureter and Urethera), Advanced Cancer, Metastatic Cancer
Interventions
INCB047986, Gemcitabine, nab-paclitaxel
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
Atlanta, Georgia • Nashville, Tennessee • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Oct 11, 2026, 2:33 AM EDT
Recruiting Phase 2 Interventional

Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients

NCT05604131
View directory record Official record
Conditions
Acute Myocardial Infarction Type 1
Interventions
Deferiprone Tablets, Placebo
Drug
Lead sponsor
Rohan Dharmakumar
Other
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
2
States / cities
Indianapolis, Indiana • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 11, 2026, 2:33 AM EDT
Withdrawn Phase 2 Interventional

Phase II Study of Daratumumab Pre-Mobilization and Post-ASCT in Multiple Myeloma

NCT04230031
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Daratumumab
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 21, 2022 · Synced Oct 11, 2026, 2:33 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Investigation of Psychedelic Effects in Psychoactive Substances

NCT06772753
View directory record Official record
Conditions
Psychedelic Effects in Healthy Volunteers
Interventions
Placebo, Psilocybin, Ketamine, Dextromethorphan (DXM), Dimethyltryptamine (DMT), Methylenedioxymethamphetamine (MDMA), Tetrahydrocannabinol (THC)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
25 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 11, 2026, 2:33 AM EDT
Completed Not applicable Interventional

Reduction of Environmental Tobacco Smoke (ETS) Exposure In Pediatric Cancer Patients

NCT00766766
View directory record Official record
Conditions
Cancer
Interventions
Health Risk and Behavioral Skills Coaching Sessions, Telephone Coaching Sessions, Physician Feedback Letter
Behavioral
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 17 Years
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 6, 2013 · Synced Oct 11, 2026, 2:33 AM EDT
Completed Not applicable Interventional Results available

Modulating Impulsivity in Suicidal Adolescents With Transcranial Direct Current Stimulation (tDCS)

NCT03365102
View directory record Official record
Conditions
Impulsive Behavior
Interventions
anodal tDCS over the rIFG,, anodal tDCS over the lOFC,, sham tDCS stimulation condition
Device
Lead sponsor
Lifespan
Other
Eligibility
13 Years to 17 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Riverside, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 2, 2022 · Synced Oct 11, 2026, 2:33 AM EDT